Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial

Abstract

In this pilot safety study of 48 patients with mild or moderate asthma who had bronchial reactivity to adenosine monophosphate, regadenoson was safe and well tolerated.

ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers

“…Two small pilot studies of moderate to severe COPD and moderate asthma showed no statistically significant difference between regadenoson and placebo in bronchoconstrictive reactions as measured by spirometry. 32,33 While several other studies have examined the issue, 34 the only randomized study enrolled 999 patients with spirometry defined COPD or asthma and found no difference in the rate of bronchoconstriction between regadenoson and placebo, but did find more dyspnea. 35 …”

Adverse effects associated with regadenoson myocardial perfusion imaging

“…4,35,39,40 Following initial post-marketing reports of wheezing, dyspnea, and respiratory arrest, 16 the use of regadenoson in patients with COPD and/or asthma was examined in randomized, double-blinded, cross-over, placebo-controlled trials that included patients with moderate-severe COPD (RegCOPD) and mild-moderate asthma (RegAsthma). 41,42 These showed that use of regadenoson in the above patient subgroups was well tolerated without significant changes in respiratory rate, FVC, FEV1, new-onset wheezing, or bronchoconstriction and oxygen saturation compared to placebo. 41,42 Of note, dyspnea was reported in 61% of patients in the regadenoson group vs 0% in the placebo group, this however, was not confirmed by objective measurements.…”

Nuclear Cardiology: 2014 Innovations and Developments

“…[12][13][14][15] In two early, small, double-blind, placebo-controlled, crossover studies, regadenoson did not reduce forced expiratory volume in 1 second (FEV1) on serial pulmonary function testing or oxygen saturation as compared to placebo saline infusion. A more recent double-blind, randomized, placebo-controlled trial of 999 subjects (532 with asthma and 467 with COPD) evaluated the effects of regadenoson vs saline infusion using serial pulmonary function tests over a several-hour period postinjection.…”